Rifampicin

By Targets:	Antibiotic (9) Bacterial (9) Cytochrome P450 (2) Fungal (2) Influenza Virus (5) Isotope-Labeled Compounds (3) Orthopoxvirus (2)
By Research Areas:	Cancer (4) Infection (12) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0272

*Rifampicin* Maximum Cited Publications 20 Publications Verification Rifampin; Rifamycin AMP	Bacterial Influenza Virus Antibiotic Orthopoxvirus	Infection Cancer
Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.

HY-B0272S2

Rifampicin-d4 Rifampin-d₄; Rifamycin AMP-d₄	Bacterial Influenza Virus Antibiotic	Infection
Rifampicin-d₄ is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities.

HY-B0272R

Rifampicin (Standard) Rifampin (Standard); Rifamycin AMP (Standard)	Bacterial Influenza Virus Antibiotic Orthopoxvirus	Infection Cancer
Rifampicin (Standard) is the analytical standard of Rifampicin. This product is intended for research and analytical applications. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.

HY-B0272S

Rifampicin-d3 Rifampin-d₃; Rifamycin AMP-d₃	Bacterial Influenza Virus Antibiotic	Infection
Rifampicin-d₃ is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities[1][2].

HY-B0272S1

Rifampicin-d8 Rifampin-d₈; Rifamycin AMP-d₈	Bacterial Influenza Virus Antibiotic	Infection
Rifampicin-d8 (Rifampin-d8) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities.

HY-B0272S3

Rifampicin-d11 Rifampin-d₁₁; Rifamycin AMP-d₁₁	Isotope-Labeled Compounds	Others
Rifampicin-d₁₁ (Rifampin-d₁₁; Rifamycin AMP-d₁₁)is the deuterium labeledRifampicin(HY-B0272) . Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity .

HY-125587S

25-Desacetyl Rifampicin-d3

Isotope-Labeled Compounds Others

25-Desacetyl Rifampicin-d₃ is the deuterium labeled 25-Desacetyl Rifampicin[1].
HY-125587S1

25-Desacetyl rifampicin-d4

DesacetylRifampicin-d₄
Isotope-Labeled Compounds Others

25-Desacetyl rifampicin-d4 (Desacetylrifampicin-d4) is deuterated-labeled 25-Desacetyl rifampicin .

*25-Desacetyl Rifampicin-d3*	Isotope-Labeled Compounds	Others
25-Desacetyl Rifampicin-d₃ is the deuterium labeled 25-Desacetyl Rifampicin[1].

*25-Desacetyl rifampicin-d4* DesacetylRifampicin-d₄	Isotope-Labeled Compounds	Others
25-Desacetyl rifampicin-d4 (Desacetylrifampicin-d4) is deuterated-labeled 25-Desacetyl rifampicin .

HY-N3241

Mucrolidin	Bacterial	Infection
Mucrolidin is an eudesmane-type sesquiterpenoid isolated from aerial parts of homalomena occulta. Mucrolidin exhibits weak antibacterial activities when it compares to Rifampicin (HY-B0272) .

HY-B1324A

Oxiconazole Ro 13-8996 free base	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole (Ro 13-8996) is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-B1324

Oxiconazole nitrate 1 Publications Verification Ro 13-8996	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole (Ro 13-8996) nitrate is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole nitrate is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole nitrate exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-129043

3-Formyl rifamycin

Antibiotic Infection

3-Formyl rifamycin is an intermediate of Rifampicin.

3-Formyl rifamycin	Antibiotic	Infection
3-Formyl rifamycin is an intermediate of Rifampicin.

HY-129043R

3-Formyl rifamycin (Standard)	Antibiotic	Infection
3-Formyl rifamycin (Standard) is the analytical standard of 3-Formyl rifamycin. This product is intended for research and analytical applications. 3-Formyl rifamycin is an intermediate of Rifampicin.

HY-P5680

SpHistin	Bacterial	Inflammation/Immunology
SpHistin is an antimicrobial peptide (AMP). SpHistin can bind to LPS (HY-D1056) and permeabilize the bacterial membrane. SpHistin combined with Rifampicin (HY-B0272) and Azithromycin (HY-17506) promotes the intracellular uptake of the antibiotics and subsequently enhances the bactericidal activity of both agents against P. aeruginosa .

HY-161395

IDD-8E	Bacterial	Infection
IDD-8E is an effective anti-pseudomonal agent (MIC =4.4 µM ) with no cytotoxicity. IDD-8E shows significant pseudomonal killing and disruption of pseudomonal biofilm. IDD-8E binds to the ATP-binding pocket of WaaP and also inhibits other ESKAPE pathogens.

HY-P5704

K11	Bacterial	Infection
K11 is an antimicrobial peptide. K11 is active against MDR/XDR K. pneumoniae isolates (MIC: 8-512 μg/mL), and inhibits bacterial biofilm formation. K11 can act synergistically with antibiotics (Chloramphenicol (HY-B0239), Meropenem (HY-13678), Rifampicin (HY-B0272), etc.) against drug-resistant K. pneumoniae. K11 has high thermal and wide pH stability .

Cat. No.	Product Name

HY-L142

Anti-tuberculosis Compound Library	94 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases. Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs. MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Anti-tuberculosis Compound Library

94 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Target	Research Area